pharmaphorum January 14, 2024
The FDA has opened a comment period, extending until the end of the month, that is seeking information on how digital health technologies (DHTs) might be deployed to help prevent, detect and manage diabetes.
The call has gone out from Troy Tazbaz, the ex-Oracle executive who was recently appointed director of the FDA’s Digital Health Centre of Excellence, (DHCoE). Tazbaz wants to involve as many stakeholders as possible – patients, researchers, healthcare providers, medical product manufacturers, technology companies, standards organisations, and others – as it refines the regulations for digital interventions.
The consultation is asking how DHTs can extend care into people’s homes and communities, play a role in early detection and prevention of the disease, and potentially even help...
Today's Sponsors
Today's Sponsor